Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis

Bone Marrow Transplant. 2018 Jan;53(1):105-107. doi: 10.1038/bmt.2017.220. Epub 2017 Nov 13.

Authors

S Pagliuca¹, A M Risitano², F S De Fontbrune¹, M Robin¹, A P Iori³, S Marotta², D Michonneau¹, A Villate⁴, D Desmier⁵, G Socié¹, R P De Latour¹

Affiliations

¹ Department of Hematology and Transplant Unit, APHP Saint Louis Hospital, Paris, France.
² Department of Hematology and Transplant Unit, University Federico II of Naples, Naples, Italy.
³ Department of Bone marrow transplantion, University La Sapienza, Rome, Italy.
⁴ Department of Heamtology Centre Hospitalier Régional Universitaire de Tours, Tours, France.
⁵ Department of Hematology Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

PMID: 29131151
DOI: 10.1038/bmt.2017.220

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Anemia, Aplastic / drug therapy*
Anemia, Aplastic / pathology
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Hemoglobinuria, Paroxysmal / drug therapy*
Hemoglobinuria, Paroxysmal / pathology
Humans
Immunosuppression Therapy / methods*
Retrospective Studies
Young Adult

Substances

Antibodies, Monoclonal, Humanized
eculizumab